A multicentre randomized open‐label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia
British Journal of Haematology · 2026-08 · 209 (2) · 682-690
DOI: 10.1111/bjh.70574 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, online erschienen am 24.05.2026. Verfasst von Haoyi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Dexamethasone, Glycyrrhizic Acid, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Major Fundamental Research Project of Shandong Province.
Abstract (Originalsprache)
Standard first‐line therapy with dexamethasone requires further optimization due to unsatisfying long‐term outcomes in patients with primary immune thrombocytopenia (ITP). Previous research suggested that glycyrrhizinate induces platelet responses in ITP murine models. This study aimed to compare the efficacy and safety of dexamethasone plus glycyrrhizinate with dexamethasone in patients with newly diagnosed ITP. Eligible patients aged ≥18 years with newly diagnosed, treatment‐naïve ITP who had baseline platelet count of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, China.
- Department of Hematology, Qilu Hospital of Shandong University, Shandong University, Qingdao, China.
- Department of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
- Department of Hematology, Liaocheng People's Hospital, Liaocheng, China.
- Department of Hematology, Tai'an Central Hospital, Tai'an, China.
- Department of Hematology, The First Affiliated Hospital of Weifang Medical University, Weifang, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Major Fundamental Research Project of Shandong Province
- Distinguished Young and Middle-aged Scholar Foundation of Shandong University
- ECCM Program of Clinical Research Center of Shandong University
Zitieren
APA
Wang, H., Wang, R., Yuan, C., Bi, K., Xiao, T., Teng, Q., Wang, H., Yu, J., Hou, M., & Hou, Y. (2026). A multicentre randomized open‐label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia. British Journal of Haematology, 209(2), 682-690. https://doi.org/10.1111/bjh.70574
Vancouver
Wang H, Wang R, Yuan C, Bi K, Xiao T, Teng Q, et al. A multicentre randomized open‐label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia. British Journal of Haematology. 2026;209(2):682-690. doi:10.1111/bjh.70574
BibTeX
@article{Wang2026,
author = {Wang, Haoyi and Wang, Ruting and Yuan, Chenglu and Bi, Kehong and Xiao, Taiwu and Teng, Qingliang and Wang, Haiying and Yu, Jie and Hou, Ming and Hou, Yu},
title = {A multicentre randomized open‐label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {2},
pages = {682--690},
doi = {10.1111/bjh.70574}
}
EUVIMED